Skip to content

Breakthrough mRNA vaccine delivery targets lymph nodes with precision

A revolutionary mRNA vaccine could transform cancer treatment. By hijacking immune cells, it delivers therapy straight to where it's needed most—lymph nodes.

The image shows a diagram of a protein molecule with the words "polymerase ii" and "RNA" written on...
The image shows a diagram of a protein molecule with the words "polymerase ii" and "RNA" written on it against a white background.

Breakthrough mRNA vaccine delivery targets lymph nodes with precision

Scientists have created a new mRNA vaccine delivery system that targets lymph nodes with precision. The technology aims to overcome key challenges faced by traditional cancer vaccines, such as poor migration to lymph nodes and unwanted accumulation in organs like the liver. Early tests show promising results in boosting immune responses while reducing side effects. The system uses a specially designed polyplex made of mRNA combined with a modified low-molecular-weight polyethylenimine (PEI). This polymer is functionalised with cyclic disulfides, which help it bind specifically to the transferrin receptor on monocytes—a type of white blood cell. This targeted interaction improves stability and cuts down on off-target uptake in the liver, a common issue with older mRNA delivery methods.

When injected under the skin, the polyplexes trigger innate immunity and attract monocytes to the injection site. These cells then act as carriers, transporting the mRNA payload to nearby lymph nodes. Once there, the mRNA is translated, kickstarting a strong adaptive immune response. Testing across different tumour models has confirmed the system’s effectiveness. It successfully generated robust cytotoxic T cell activity, slowing melanoma tumour growth and blocking metastasis. The subcutaneous injection method also makes the treatment more accessible, improving patient compliance and suitability for clinical use.

The new delivery platform reduces liver uptake, lowering systemic toxicity and improving patient tolerability. Its ability to elicit strong immune responses across various tumour types suggests broad potential for cancer immunotherapy. Researchers now aim to advance the technology toward wider clinical testing and adoption.

Read also:

Latest